Medical White Papers

RSS

Medical White Papers are in-depth articles aimed to educate and inform site visitors interested in medical research. Some of these papers are derived from sources where we have existing commercial relationships. Such articles are clearly labelled as sponsored content and are only accepted when the content is deemed to add value to the core editorial ethos of News Medical.

Dual targeting of both LILRB and HLA-G for an effective anti-cancer immunotherapy combination

Dual targeting of both LILRB and HLA-G for an effective anti-cancer immunotherapy combination

In this article, ACROBiosystems discusses a new immunotherapy combination targeting both Leukocyte Immunoglobulin-like Receptor Bs (LILRBs) and Human Leukocyte Antigen G (HLA-G) that has shown to promote innate and adaptive anti-cancer immunity.

From ACROBiosystems 19 May 2022

18 common questions about the new European Pharmacopoeia (Ph.Eur.) Chapter 2.1.7

18 common questions about the new European Pharmacopoeia (Ph.Eur.) Chapter 2.1.7

In this article, Sartorius answers 18 common questions about the new European Pharmacopoeia regulations - Chapter 2.1.7 “Balances for analytical purposes.”

From Sartorius Lab Instruments GmbH & Co. KG 21 Apr 2022

The science behind CBD-infused beverages

The science behind CBD-infused beverages

In recent years, products containing Cannabidiol (CBD) have become increasingly popular, from chocolates to oils. In this article, LECO uses GCxGC-MS analysis to characterize beverage products containing CBD and explain the science behind it.

From LECO Corporation 7 Apr 2022

How Cerba supports patients through companion diagnostics

How Cerba supports patients through companion diagnostics

This article details how Cerba Research makes use of its extensive network of highly qualified professionals and state-of-the-art equipment to expertly develop companion diagnostic tests that allow clients to gauge the safety of a specific product.

From Cerba Research 6 Apr 2022

Achieve better routine testing thanks to Cerba's broad portfolio

Achieve better routine testing thanks to Cerba's broad portfolio

Clinical trials heavily rely on routine testing. Cerba Research's broad portfolio offers a wide range of evaluations in hematology, biochemistry, serology, and urinalysis.

From Cerba Research 5 Apr 2022

Cerba Research offers large-scale sequencing

Cerba Research offers large-scale sequencing

Cerba Research is a leader in NGS sequencing and has worked to reduce turnaround times and offer rapid response to any sequencing-related needs.

From Cerba Research 5 Apr 2022

Three critical lab capabilities to look for in immuno-oncology

Three critical lab capabilities to look for in immuno-oncology

Immuno-oncology is a booming sector where insights need to be generated and analyzed as early as possible to optimize procedures. Cerba Research shares the three critical central lab capabilities to look for in a partner lab to achieve these results.

From Cerba Research 5 Apr 2022

Inflammatory and autoimmune diseases are underlying causes of a variety of human diseases

Inflammatory and autoimmune diseases are underlying causes of a variety of human diseases

This article underlines how Cerba Research uses its network of highly-qualified professionals and state-of-the-art equipment to boost research on inflammatory and autoimmune diseases.

From Cerba Research 5 Apr 2022

Biomarkers hold the key to more personalized medicine

Biomarkers hold the key to more personalized medicine

As the need for personalized medicine is made more apparent by the inefficiency of some treatments against particular illnesses, biomarkers are offering benefits in the drug development process that cannot be overlooked.

From Cerba Research 5 Apr 2022

Cerba strives to boost research in immuno-oncology

Cerba strives to boost research in immuno-oncology

Immuno-oncology is a promising cancer treatment approach that relies on immune regulation. It is particularly interesting as it could offer solutions for cancers that resist other forms of treatment.

From Cerba Research 5 Apr 2022

Cerba’s ‘patient first’ ideology is at the heart of its identity

Cerba’s ‘patient first’ ideology is at the heart of its identity

Cerba's mission is to help improve clinical trials, but the ultimate goal is to make patients' lives easier. We are striving for safer, more comfortable processes to relieve patients of unnecessary stress, and that has been at the heart of Cerba's approach from the very first day.

From Cerba Research 5 Apr 2022

Cerba Research partners with the Gustave Roussy Institute to improve patient experience

Cerba Research partners with the Gustave Roussy Institute to improve patient experience

Immuno-oncology (IO) trials can be a great chance for participating patients to fight cancer, but the complex logistics behind them can prove difficult for the patient.

From Cerba Research 5 Apr 2022

The power of flow cytometry in cancer research

The power of flow cytometry in cancer research

Flow cytometry is used in immunotherapy research to measure and monitor immune responses.

From Cerba Research 5 Apr 2022

Biomarkers hold the key to better clinical outcomes

Biomarkers hold the key to better clinical outcomes

Biomarkers hold the key to more efficient, more successful drug development and can remedy this issue.

From Cerba Research 5 Apr 2022

Custom flow cytometry assays are critical to personalized medicine

Custom flow cytometry assays are critical to personalized medicine

Cerba Research have 25 years of extensive expertise in providing Phase I to Phase III flow cytometry testing for clinical trials, and are proud of a strong track record of developing custom-made flow cytometry panels.

From Cerba Research 5 Apr 2022

Cerba Research offers state-of-the-art in-vitro diagnostics

Cerba Research offers state-of-the-art in-vitro diagnostics

Cerba offers in-vitro diagnostics to boost and optimize client trials and your testing potential.

From Cerba Research 5 Apr 2022

Optimize clinical trials with Cerba Research high-end operational support

Optimize clinical trials with Cerba Research high-end operational support

From logistics to data management, high-end operational support is key for Cerba and its partners.

From Cerba Research 5 Apr 2022

Alleviating the complexity of rare disease research

Alleviating the complexity of rare disease research

Rare diseases can be especially difficult to research - be it because of staff shortages or access to remote sites.

From Cerba Research 5 Apr 2022

Rapid innovations in histopathology will change the face of clinical trials

Rapid innovations in histopathology will change the face of clinical trials

Histopathology is undergoing rapid innovations due to the rise of precision medicine.

From Cerba Research 5 Apr 2022

Cerba Research extends facilities provided by U.S Immuno-Oncology Center of Excellence

Cerba Research extends facilities provided by U.S Immuno-Oncology Center of Excellence

This article outlines how Cerba Research U.S benefited from moving their Center of Excellence to a larger facility.

From Cerba Research 5 Apr 2022

Previous
1
...
32
33
34
35
36
37
38
...
49
Next

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.